These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 22863764)

  • 21. HCV burden in Europe and the possible impact of current treatment.
    Mathurin P
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S314-7. PubMed ID: 24091109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of peginterferon maintenance therapy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus.
    Shiffman ML
    Oncology; 2010 Jul; 78 Suppl 1():11-6. PubMed ID: 20616578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease burden of chronic hepatitis C among immigrants in Canada.
    Chen W; Krahn M
    J Viral Hepat; 2015 Dec; 22(12):1043-54. PubMed ID: 26110922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France.
    Deuffic-Burban S; Babany G; Lonjon-Domanec I; Deltenre P; Canva-Delcambre V; Dharancy S; Louvet A; Roudot-Thoraval F; Mathurin P
    Hepatology; 2009 Nov; 50(5):1351-9. PubMed ID: 19676130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study.
    Ok KS; Jeong SH; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Bae SH; Lee HC
    Medicine (Baltimore); 2016 Aug; 95(35):e4594. PubMed ID: 27583874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C: epidemiology, diagnosis, natural history and therapy.
    Pol S; Vallet-Pichard A; Corouge M; Mallet VO
    Contrib Nephrol; 2012; 176():1-9. PubMed ID: 22310776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study.
    Bruno S; Crosignani A; Facciotto C; Rossi S; Roffi L; Redaelli A; de Franchis R; Almasio PL; Maisonneuve P
    Hepatology; 2010 Jun; 51(6):2069-76. PubMed ID: 20196120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments.
    Sypsa V; Touloumi G; Papatheodoridis GV; Tassopoulos NC; Ketikoglou I; Vafiadis I; Hatzis G; Tsantoulas D; Akriviadis E; Koutsounas S; Hatzakis A
    J Viral Hepat; 2005 Sep; 12(5):543-50. PubMed ID: 16108772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand.
    Gane E; Stedman C; Brunton C; Radke S; Henderson C; Estes C; Razavi H
    N Z Med J; 2014 Dec; 127(1407):61-74. PubMed ID: 25530333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From current status to optimization of HCV treatment: Recommendations from an expert panel.
    Craxì A; Perno CF; Viganò M; Ceccherini-Silberstein F; Petta S;
    Dig Liver Dis; 2016 Sep; 48(9):995-1005. PubMed ID: 27388261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on hepatitis C: epidemiology, treatment and resistance to antiviral therapies.
    Ness E; Kowdley KV
    Minerva Gastroenterol Dietol; 2015 Sep; 61(3):145-58. PubMed ID: 25990619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
    Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT).
    Fontaine H; Maynard M; Bouix C; Carrieri MP; Botta-Fridlund D; D'Alteroche L; Conti F; Pageaux GP; Leroy V; Métivier S; Anty R; Durand F; Canva V; Vilotitch A; Lebray P; Alric L; Duvoux C; Petrov-Sanchez V; Beaulieux F; Wellems C; Paul C; Roque-Afonso AM; Roche B; Pradat P; Samuel D; Duclos-Vallée JC;
    Clin Res Hepatol Gastroenterol; 2017 Feb; 41(1):56-65. PubMed ID: 27554134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral treatment for cirrhosis due to hepatitis C: a review.
    Somasundaram A; Venkataraman J
    Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of chronic hepatitis C patients treated with interferon-alpha: risk of cirrhosis and hepatocellular carcinoma in a single center over 10 years.
    Lee HJ; Yeon JE; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Kim JH; Seo YS; Yim HJ; Byun KS
    Intervirology; 2015; 58(1):14-21. PubMed ID: 25592614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus: Promising discoveries and new treatments.
    Bastos JC; Padilla MA; Caserta LC; Miotto N; Vigani AG; Arns CW
    World J Gastroenterol; 2016 Jul; 22(28):6393-401. PubMed ID: 27605875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward).
    Dore GJ; Ward J; Thursz M
    J Viral Hepat; 2014 May; 21 Suppl 1():1-4. PubMed ID: 24713003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.